The Reduction of Heterotopic Ossification Incidence After Hip Arthroscopy in Patients Treated With Selective Cyclooxygenase 2 Inhibitor (Celecoxib)

Published:November 13, 2019DOI:


      To evaluate the effectiveness of celecoxib, a selective cyclooxygenase 2 inhibitor, in reducing heterotopic ossification (HO) after hip arthroscopic surgery and to evaluate celecoxib’s impact on clinical outcomes.


      We performed a retrospective review of patients who received hip arthroscopy performed by the same surgeon between January 1, 2012, and December 31, 2016. Patients who had an allergy to sulfa drugs, had pre-existing HO or previous surgery on the operative side, or failed to complete radiographic follow-up at 6 months postoperatively were excluded. Patients in the treatment group received 400 mg of celecoxib postoperatively for 6 weeks, whereas the control group received no postoperative celecoxib. The incidence of HO was assessed using anteroposterior radiographs obtained at 6 months, 1 year, and 2 years postoperatively. Patients completed the International Hip Outcome Tool 33 survey, and the proportion of patients who met the minimal clinically important difference, substantial clinical benefit (SCB), and absolute SCB was calculated.


      A total of 559 patients were identified. After application of the exclusion criteria, 454 patients were included in the study (211 in control group and 243 in treatment group). The overall incidence of HO was 20.3% (n = 92). The treatment group had a significantly lower incidence of HO at 6 months (P = .006), 1 year (P < .001), and 2 years (P = .008) postoperatively. At 2 years postoperatively, the treatment group had a significantly higher International Hip Outcome Tool 33 score on average: 64.2 versus 57.3 (P = .023). No significant difference in the proportion of patients reaching the minimal clinically important difference, SCB, or absolute SCB was found at any of the postoperative time points.


      The findings of this study suggest that a prophylactic treatment regimen of 400 mg of celecoxib once daily for 6 weeks significantly reduces the incidence of HO formation after hip arthroscopic surgery; however, it did not impact clinical outcomes.

      Level of Evidence

      Level III, retrospective, comparative case-control study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Firoozabadi R.
        • Alton T.
        • Sagi H.C.
        Heterotopic ossification in acetabular fracture surgery.
        J Am Acad Orthop Surg. 2017; 25: 117-124
        • Amar E.
        • Sharfman Z.T.
        • Rath E.
        Heterotopic ossification after hip arthroscopy.
        J Hip Preserv Surg. 2015; 2: 355-363
        • Hoyt B.W.
        • Pavey G.J.
        • Potter B.K.
        • Forsberg J.A.
        Heterotopic ossification and lessons learned from fifteen years at war: A review of therapy, novel research, and future directions for military and civilian orthopaedic trauma.
        Bone. 2018; 109: 3-11
        • Winkler S.
        • Craiovan B.
        • Wagner F.
        • Weber M.
        • Grifka J.
        • Renkawitz T.
        Pathogenesis and prevention strategies of heterotopic ossification in total hip arthroplasty: A narrative literature review and results of a survey in Germany.
        Arch Orthop Trauma Surg. 2015; 135: 481-489
        • Bohner M.
        • Miron R.J.
        A proposed mechanism for material-induced heterotopic ossification.
        Mater Today. 2019; 22: 132-141
        • Wang H.
        • Lindborg C.
        • Lounev V.
        • et al.
        Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling.
        J Bone Miner Res. 2016; 31: 1652-1665
        • Bozic K.J.
        • Chan V.
        • Valone F.H.
        • Feeley B.T.
        • Vail T.P.
        Trends in hip arthroscopy utilization in the United States.
        J Arthroplasty. 2013; 28: 140-143
        • Degen R.M.
        • Bernard J.A.
        • Pan T.J.
        • et al.
        Hip arthroscopy utilization and associated complications: A population-based analysis.
        J Hip Preserv Surg. 2017; 4: 240-249
        • Maradit Kremers H.
        • Schilz S.R.
        • Van Houten H.K.
        • et al.
        Trends in utilization and outcomes of hip arthroscopy in the United States between 2005 and 2013.
        J Arthroplasty. 2017; 32: 750-755
        • Rath E.
        • Sherman H.
        • Sampson T.G.
        • Ben Tov T.
        • Maman E.
        • Amar E.
        The incidence of heterotopic ossification in hip arthroscopy.
        Arthroscopy. 2013; 29: 427-433
        • Kan S.L.
        • Yang B.
        • Ning G.Z.
        • et al.
        Nonsteroidal anti-inflammatory drugs as prophylaxis for heterotopic ossification after total hip arthroplasty: A systematic review and meta-analysis.
        Medicine (Baltimore). 2015; 94: e828
        • Yeung M.
        • Jamshidi S.
        • Horner N.
        • Simunovic N.
        • Karlsson J.
        • Ayeni O.R.
        Efficacy of nonsteroidal anti-inflammatory drug prophylaxis for heterotrophic ossification in hip arthroscopy: A systematic review.
        Arthroscopy. 2016; 32: 519-525
        • Newman E.A.
        • Holst D.C.
        • Bracey D.N.
        • Russell G.B.
        • Lang J.E.
        Incidence of heterotopic ossification in direct anterior vs posterior approach to total hip arthroplasty: A retrospective radiographic review.
        Int Orthop. 2016; 40: 1967-1973
        • Milakovic M.
        • Popovic M.
        • Raman S.
        • Tsao M.
        • Lam H.
        • Chow E.
        Radiotherapy for the prophylaxis of heterotopic ossification: A systematic review and meta-analysis of randomized controlled trials.
        Radiother Oncol. 2015; 116: 4-9
        • Bedi A.
        • Zbeda R.M.
        • Bueno V.F.
        • Downie B.
        • Dolan M.
        • Kelly B.T.
        The incidence of heterotopic ossification after hip arthroscopy.
        Am J Sports Med. 2012; 40: 854-863
        • Suero E.M.
        • Meindl R.
        • Schildhauer T.A.
        • Citak M.
        Clinical prediction rule for heterotopic ossification of the hip in patients with spinal cord injury.
        Spine (Phila Pa 1976). 2018; 43: 1572-1578
        • Vavken P.
        • Castellani L.
        • Sculco T.P.
        Prophylaxis of heterotopic ossification of the hip: Systematic review and meta-analysis.
        Clin Orthop Relat Res. 2009; 467: 3283-3289
        • Beckmann J.T.
        • Wylie J.D.
        • Kapron A.L.
        • Hanson J.A.
        • Maak T.G.
        • Aoki S.K.
        The effect of NSAID prophylaxis and operative variables on heterotopic ossification after hip arthroscopy.
        Am J Sports Med. 2014; 42: 1359-1364
        • Beckmann J.T.
        • Wylie J.D.
        • Potter M.Q.
        • Maak T.G.
        • Greene T.H.
        • Aoki S.K.
        Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: A double-blind randomized placebo-controlled trial.
        J Bone Joint Surg Am. 2015; 97: 2032-2037
        • Nossa J.M.
        • Aguilera B.
        • Márquez W.
        • et al.
        Factors associated with hip arthroscopy complications in the treatment of femoroacetabular impingement.
        Curr Orthop Pract. 2014; 25: 362-366
        • Randelli F.
        • Pierannunzii L.
        • Banci L.
        • Ragone V.
        • Aliprandi A.
        • Buly R.
        Heterotopic ossifications after arthroscopic management of femoroacetabular impingement: The role of NSAID prophylaxis.
        J Orthop Traumatol. 2010; 11: 245-250
        • Rath E.
        • Warschawski Y.
        • Maman E.
        • et al.
        Selective COX-2 inhibitors significantly reduce the occurrence of heterotopic ossification after hip arthroscopic surgery.
        Am J Sports Med. 2016; 44: 677-681
        • Patrono C.
        • Baigent C.
        Coxibs, Traditional NSAIDs, and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now.
        Clin Pharmacol Ther. 2017; 102: 238-245
        • Zhu X.T.
        • Chen L.
        • Lin J.H.
        Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis.
        Medicine (Baltimore). 2018; 97: e11649
        • Nissen S.E.
        • Yeomans N.D.
        • Solomon D.H.
        • et al.
        Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.
        N Engl J Med. 2016; 375: 2519-2529
        • Kahlenberg C.A.
        • Patel R.M.
        • Knesek M.
        • Tjong V.K.
        • Sonn K.
        • Terry M.A.
        Efficacy of celecoxib for early postoperative pain management in hip arthroscopy: A prospective randomized placebo-controlled study.
        Arthroscopy. 2017; 33: 1180-1185
        • Lavernia C.J.
        • Contreras J.S.
        • Villa J.M.
        • Rossi M.D.
        Celecoxib and heterotopic bone formation after total hip arthroplasty.
        J Arthroplasty. 2014; 29: 390-392
        • Hug K.T.
        • Alton T.B.
        • Gee A.O.
        Classifications in brief: Brooker classification of heterotopic ossification after total hip arthroplasty.
        Clin Orthop Relat Res. 2015; 473: 2154-2157
        • Brooker A.F.
        • Bowerman J.W.
        • Robinson R.A.
        • Riley Jr., L.H.
        Ectopic ossification following total hip replacement. Incidence and a method of classification.
        J Bone Joint Surg Am. 1973; 55: 1629-1632
        • Mohtadi N.G.
        • Griffin D.R.
        • Pedersen M.E.
        • et al.
        The development and validation of a self-administered quality-of-life outcome measure for young, active patients with symptomatic hip disease: The International Hip Outcome Tool (iHOT-33).
        Arthroscopy. 2012; 28 (595, 605, quiz 606-610.e1)
        • Nwachukwu B.U.
        • Chang B.
        • Fields K.
        • et al.
        Defining the "substantial clinical benefit" after arthroscopic treatment of femoroacetabular impingement.
        Am J Sports Med. 2017; 45: 1297-1303
        • Løken S.
        Hip arthroscopy and heterotopic ossification: Is NSAID prophylaxis justified? Commentary on an article by James T. Beckmann, MD, MS, et al.
        "Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: A double-blind randomized placebo-controlled trial." J Bone Joint Surg Am. 2015; 97: e80